Research programme: antibody and small molecule therapeutics - Applied Immunotherapeutics/Feinstein Institute for Medical Research

Drug Profile

Research programme: antibody and small molecule therapeutics - Applied Immunotherapeutics/Feinstein Institute for Medical Research

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karolinska Institute; The Feinstein Institute for Medical Research
  • Class Anti-inflammatories; Antianaemics; Antibodies; Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action HMGB1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Anaemia; Autoimmune disorders; Diabetes mellitus; Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 12 Jul 2017 Feinstein Institute and Applied Immunotherapeutics agree to co-develop antibodies and small molecule therapeutics for inflammatory and autoimmune diseases
  • 12 Jul 2017 Early research in Anaemia in Sweden, USA
  • 12 Jul 2017 Early research in Autoimmune disorders in Sweden, USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top